- Home
- BEAM vs AZTA Comparison
BEAM vs AZTA Comparison
Compare BEAM & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- AZTA
- Stock Information
- Founded
- BEAM 2017
- AZTA 1978
- Country
- BEAM United States
- AZTA United States
- Employees
- BEAM N/A
- AZTA N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- AZTA Industrial Machinery/Components
- Sector
- BEAM Health Care
- AZTA Technology
- Exchange
- BEAM Nasdaq
- AZTA Nasdaq
- Market Cap
- BEAM 1.8B
- AZTA 1.8B
- IPO Year
- BEAM 2020
- AZTA 1995
- Fundamental
- Price
- BEAM $17.00
- AZTA $25.25
- Analyst Decision
- BEAM Strong Buy
- AZTA Buy
- Analyst Count
- BEAM 11
- AZTA 3
- Target Price
- BEAM $50.50
- AZTA $57.00
- AVG Volume (30 Days)
- BEAM 3.0M
- AZTA 876.0K
- Earning Date
- BEAM 05-06-2025
- AZTA 05-07-2025
- Dividend Yield
- BEAM N/A
- AZTA N/A
- EPS Growth
- BEAM N/A
- AZTA N/A
- EPS
- BEAM N/A
- AZTA N/A
- Revenue
- BEAM $63,518,000.00
- AZTA $662,108,000.00
- Revenue This Year
- BEAM N/A
- AZTA N/A
- Revenue Next Year
- BEAM $6.32
- AZTA $5.44
- P/E Ratio
- BEAM N/A
- AZTA N/A
- Revenue Growth
- BEAM N/A
- AZTA 5.36
- 52 Week Low
- BEAM $13.53
- AZTA $25.36
- 52 Week High
- BEAM $35.25
- AZTA $63.58
- Technical
- Relative Strength Index (RSI)
- BEAM 40.71
- AZTA 27.55
- Support Level
- BEAM $16.04
- AZTA $25.36
- Resistance Level
- BEAM $17.94
- AZTA $27.89
- Average True Range (ATR)
- BEAM 1.84
- AZTA 2.31
- MACD
- BEAM 0.26
- AZTA -0.23
- Stochastic Oscillator
- BEAM 44.24
- AZTA 5.13
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.